PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has caught the eye of analysts as a top pick in the medical device sector. Back on August 8, Mike Kratky from Leerink Partners maintained his Buy rating for the company, sticking to his $83 price target. What’s fueling this optimism? For one, PROCEPT posted a surprising 4% jump in Q2 sales thanks to solid international growth and better prices in the US. Kratky noted that despite a bit of a slump in Q3, the company’s annual sales outlook was bumped up a bit, along with improved gross margin predictions, pointing to a promising end-of-year picture.
PROCEPT, a commercial-stage player in surgical robotics, is making waves with its game-changing tech for urology, like the AquaBeam Robotic System, which offers a minimally invasive option for surgery. However, while PRCT looks promising, some argue that certain AI stocks might bring better returns and less risk. Interested in a seriously undervalued AI stock poised to gain from tariffs and reshoring trends? Be sure to check out our free report on the best short-term AI investment pick.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article originally appeared at Insider Monkey.
